High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer

References

• Zhou JX, Yang H, Deng Q, et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol. 2013;24(5):1319–1325. doi:10.1093/annonc/mds626
   PubMed Web of Science ®Google Scholar
• Auliac JB, Monnet I, Dubos-Arvis C, et al. Non-Small-Cell Lung Cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 Study). Target Oncol. 2017;12(6):833–838. doi:10.1007/s11523-017-0520-7
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794
   PubMed Web of Science ®Google Scholar
• Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–21917. doi:10.18632/oncotarget.15746
   PubMedGoogle Scholar
• Ito K, Hataji O, Kobayashi H, et al. Sequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer-a multicenter retrospective study. J Thorac Oncol. 2017;12(2):390–396. doi:10.1016/j.jtho.2016.07.022
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global Phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. doi:10.1016/j.jtho.2019.03.007
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370–1379. doi:10.1200/JCO.18.02236
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117. doi:10.1126/scitranslmed.3003316
   Web of Science ®Google Scholar
• Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci. 2018;109(3):572–580. doi:10.1111/cas.13504
   PubMed Web of Science ®Google Scholar
• Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016;8(1):32–47. doi:10.1177/1758834015617355
   PubMed Web of Science ®Google Scholar
• Okada K, Araki M, Sakashita T, et al. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine. 2019;41:41105–41119.
   Web of Science ®Google Scholar
• DiBonaventura MD, Wong W, Shah-Manek B, Schulz M. Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. Onco Targets Ther. 2018;11:1175–1182.
   Web of Science ®Google Scholar
• Cadranel J, Cortot AB, Lena H, et al. Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients. ERJ Open Res. 2018;4(1):00058–2017. doi:10.1183/23120541.00058-2017
   PubMedGoogle Scholar
• Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol. 2018;36(12):1199–1206. doi:10.1200/JCO.2017.76.2294
   PubMed Web of Science ®Google Scholar
• Yang H, Wang F, Deng Q, et al. Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion. Oncol Lett. 2019;17(3):3071–3076.
   PubMed Web of Science ®Google Scholar
• Shahi RB, De Brakeleer S, Caljon B, et al. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families. BMC Cancer. 2019;19(1):313. doi:10.1186/s12885-019-5494-7
   PubMedGoogle Scholar
• Rusch M, Nakitandwe J, Shurtleff S, et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun. 2018;9(1):3962. doi:10.1038/s41467-018-06485-7
   PubMedGoogle Scholar
• Feng L, Hong S, Gao J, Li J. Whole-exome sequencing characterized the landscape of somatic mutations and pathways in colorectal cancer liver metastasis. J Oncol. 2019;20192684075. doi:10.1155/2019/2684075
   Google Scholar
• Beltran H, Eng K, Mosquera JM, et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015;1(4):466–474. doi:10.1001/jamaoncol.2015.1313
   PubMed Web of Science ®Google Scholar
• Suwinski P, Ong C, Ling MHT, et al. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:49.
   PubMed Web of Science ®Google Scholar
• Tuna M, Amos CI. Genomic sequencing in cancer. Cancer Lett. 2013;340(2):161–170. doi:10.1016/j.canlet.2012.11.004
   PubMed Web of Science ®Google Scholar
• Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;174(4):1034–1035.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Valero C, Lee M, Hoen D, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729. doi:10.1038/s41467-021-20935-9
   PubMed Web of Science ®Google Scholar
• Chen M, Xu Y, Zhao J, et al. Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer. EBioMedicine. 2019;42:304–42310.
   PubMed Web of Science ®Google Scholar
• Jiao XD, He X, Qin BD, et al. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. J Thorac Dis. 2019;11(11):4507–4515. doi:10.21037/jtd.2019.11.04
   PubMed Web of Science ®Google Scholar
• Xie LL, Shi F, Tan Z, et al. Mitochondrial network structure homeostasis and cell death. Cancer Sci. 2018;109(12):3686–3694. doi:10.1111/cas.13830
   PubMed Web of Science ®Google Scholar
• Kingnate C, Charoenkwan K, Kumfu S, Chattipakorn N, Chattipakorn SC. Possible roles of mitochondrial dynamics and the effects of pharmacological interventions in chemoresistant ovarian cancer. EBioMedicine. 2018;34:256–266.
   PubMed Web of Science ®Google Scholar
• Danish Q, Mokhdomi TA, Bukhari S, Ahmad R. The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression. Cancer Biomark. 2015;15(5):619–633. doi:10.3233/CBM-150502
   PubMed Web of Science ®Google Scholar
• Perez-Ramirez C, Canadas-Garre M, Alnatsha A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019;19(2):164–177. doi:10.1038/s41397-018-0014-8
   PubMed Web of Science ®Google Scholar
• Romano FJ, Rossetti S, Conteduca V, et al. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget. 2016;7(51):85641–85649. doi:10.18632/oncotarget.13063
   PubMedGoogle Scholar
• Mandal R, Samstein RM, Lee KW, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019;364(6439):485–491. doi:10.1126/science.aau0447
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Wang G, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78(22):6486–6496. doi:10.1158/0008-5472.CAN-18-1814
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Curtin K, Ma KN, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002;99(4):597–602. doi:10.1002/ijc.10405
   PubMed Web of Science ®Google Scholar
• Lepre MG, Omar SI, Grasso G, et al. Insights into the effect of the G245S single point mutation on the structure of p53 and the binding of the protein to DNA. Molecules. 2017;22(8):1358. doi:10.3390/molecules22081358
   PubMed Web of Science ®Google Scholar
• Suchankova J, Legartova S, Ruckova E, et al. Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after gamma-irradiation that depleted MDC1 protein in specific TP53 mutants. Histochem Cell Biol. 2017;148(3):239–255. doi:10.1007/s00418-017-1567-3
   PubMed Web of Science ®Google Scholar